Long COVID in 2026: What Actually Helps, According to the Latest Evidence

Long COVID turned recovery into a moving target for millions: symptoms that lingered for months after a "mild" infection, with no test to confirm them and no approved drug to cure them. In 2026 the picture is sharper. We now know more about what helps, what does not, and how to avoid the trap of unproven treatments. This guide translates the latest evidence into practical steps.

Key Takeaways

• By spring 2023, an estimated 52 million US adults had experienced at least one long COVID symptom; nearly 70% said symptoms limited daily activities (USC Schaeffer, 2026).
• The RECOVER-VITAL and ENERGIZE trials (March 2026) found Paxlovid and metformin did not improve established long COVID — but metformin taken early in acute infection cut risk by up to 63%.
• "Pacing" is the consensus first-line management for the subset with post-exertional malaise (PEM).
• There are still no FDA-approved treatments; management is symptom-targeted and multidisciplinary.

How Common Is Long COVID, and What Defines It?

Long COVID (post-acute sequelae of SARS-CoV-2, PASC) is generally defined as symptoms persisting more than three months after infection that are not explained by another diagnosis (NASEM consensus). The 2026 USC Schaeffer analysis estimated about 52 million US adults had at least one long COVID symptom by spring 2023, with more than a third experiencing symptoms beyond a year and nearly 70% reporting limits on daily activities.

That burden is why the condition demands serious, evidence-based care rather than dismissal. For fatigue that overlaps with other causes, our iron deficiency without anemia guide is a useful parallel read.

Evidence capsule: The 2026 RECOVER trials found 15-day and 25-day Paxlovid courses did not improve long COVID symptoms versus placebo (RECOVER-VITAL), and metformin did not help as a treatment (RECOVER ENERGIZE) — ending two major treatment hypotheses (teledirectmd clinical update, 2026).

What Does NOT Work for Established Long COVID?

Two widely hoped-for treatments failed in 2026 trials. RECOVER-VITAL found Paxlovid given as treatment did not improve symptoms. RECOVER ENERGIZE found metformin, while strong for prevention, did not treat established long COVID (teledirectmd, 2026). A 2026 narrative review confirmed only a handful of the 14 prioritized candidate treatments had any long-COVID-specific randomized evidence, and most certainty was low to very low (Frontiers in Medicine, 2026).

The honest takeaway: beware clinics or online sellers offering unproven "cleanses" or off-label cocktails. Symptom-targeted, multidisciplinary care remains the standard.

What Actually Helps: Pacing and Symptom Management

For the subset with post-exertional malaise — crashes after activity — "pacing" is the consensus first-line approach: matching activity to a sustainable energy envelope rather than pushing through. Cognitive rehab, sleep and mood support, and standard-of-care medications for specific symptoms (POTS, pain, sleep) round out management (teledirectmd, 2026).

Vaccination against COVID-19 remains the best-supported prevention, and early metformin within days of infection reduced long COVID risk by 41–63% in trials — but that window is during acute illness, not after (COVID-OUT, ACTIV-6). Our safe use of AI for health questions helps you vet claims you encounter online.

How Do You Manage Specific Symptoms?

Brain fog responds to cognitive rehabilitation and pacing of mental effort, not a pill. Post-COVID POTS is managed with fluids, salt, and sometimes beta-blockers or ivabradine. Sleep and mood are addressed with standard therapies. None of this is "one drug fixes all" — it is careful, symptom-by-symptom support from a clinician who acknowledges the condition. Our sleep and metabolism link offers related recovery context.

When Should You Seek Care?

If symptoms follow a clear infection and persist beyond three months, ask for a long COVID–informed evaluation. Red flags — chest pain, fainting, severe breathlessness, or new neurological changes — warrant prompt assessment. Because no single test confirms it, a clinician's pattern recognition and ruling out of other causes (like the iron deficiency we cover separately) matters.

Frequently Asked Questions

Is there an FDA-approved long COVID drug?

No. As of 2026 there are no FDA-approved treatments; care is symptom-targeted and multidisciplinary (Frontiers in Medicine, 2026).

Does Paxlovid cure long COVID?

No. The 2026 RECOVER-VITAL trial found Paxlovid as treatment did not improve symptoms versus placebo. It remains useful as acute-infection antiviral for eligible patients.

Does metformin help?

For prevention: yes — early metformin in acute COVID cut long COVID risk up to 63% in trials. For treatment of established long COVID: no, per RECOVER ENERGIZE (2026).

What is pacing and who needs it?

Pacing means staying within a sustainable energy limit to avoid post-exertional crashes. It is the consensus first-line management for the subset of long COVID with PEM.

Conclusion

Long COVID in 2026 is better understood but still without a cure: prevention via vaccination and early metformin works, while Paxlovid and metformin as treatments do not. Pacing and careful symptom management are the evidence-based core. If you are struggling months after infection, seek a clinician who treats this seriously, and pair self-care with the public health library.